keep vials tightly sealed until use Reconstituted solutions are recommended to be handled under appropriate laboratory conditions and used promptly according to internal SOPs Related Products IGF-1 LR3 long-acting IGF-1 analogue peptide kit HGH (Somatropin) growth hormone peptide kit BPC-157 tissue repair & healing-focused peptide kit Browse all Muscle Growth Peptide Kits THIS PRODUCT IS INTENDED FOR LABORATORY RESEARCH USE ONLY
For researchers serious about optimizing their tirzepatide protocols , SeekPeptides offers the most comprehensive resource available, with evidence-based guides, proven protocols, and a community of thousands who have navigated these exact questions
In phase 3 trials, maximal dose retatrutide demonstrated 29% placebo-adjusted weight loss at 68 weeks (albeit with higher discontinuation rates than semaglutide and tirzepatide)
A 2007 double-blind, multicenter trial (n=102) showed ALC 1,500 mg/day significantly improved tender point count, total myalgic score, depression, and musculoskeletal pain compared to placebo.[9] A 2015 RCT found ALC 1,500 mg/day comparable to duloxetine 60 mg/day for pain and depression.[8] Most notably, a 2023 RCT demonstrated that adding PEA 1,200 mg/day + ALC 2,000 mg/day to ongoing duloxetine + pregabalin therapy produced significantly greater improvements in Widespread Pain Index, FIQR, and FASmod scores.[7] Role in Treatment: ALC can be used as monotherapy or adjunctive therapy in fibromyalgia
